Serotonin and dopamine play complementary roles in gambling to recover losses.
Continued gambling to recover losses--'loss chasing'--is a prominent feature of social and pathological gambling. However, little is known about the neuromodulators that influence this behavior. In three separate experiments, we investigated the role of serotonin activity, D(2)/D(3) receptor activity, and beta-adrenoceptor activity on the loss chasing of age and IQ-matched healthy adults randomized to treatment or an appropriate control/placebo. In Experiment 1, participants consumed amino-acid drinks that did or did not contain the serotonin precursor, tryptophan. In Experiment 2, participants received a single 176 μg dose of the D(2)/D(3) receptor agonist, pramipexole, or placebo. In Experiment 3, participants received a single 80 mg dose of the beta-adrenoceptor blocker, propranolol, or placebo. Following treatment, participants completed a computerized loss-chasing game. Mood and heart rate were measured at baseline and following treatment. Tryptophan depletion significantly reduced the number of decisions made to chase losses, and the number of consecutive decisions to chase, in the absence of marked changes in mood. By contrast, pramipexole significantly increased the value of losses chased and diminished the value of losses surrendered. Propranolol markedly reduced heart rate, but produced no significant changes in loss-chasing behavior. Loss chasing can be thought of as an aversively motivated escape behavior controlled, in part, by the marginal value of continued gambling relative to the value of already accumulated losses. Serotonin and dopamine appear to play dissociable roles in the tendency of individuals to gamble to recover, or to seek to 'escape' from, previous losses. Serotonergic activity seems to promote the availability of loss chasing as a behavioral option, whereas D(2)/D(3) receptor activity produces complex changes in the value of losses judged worth chasing. Sympathetic arousal, at least as mediated by beta-adrenoceptors, does not play a major role in laboratory-based loss-chasing choices.
Campbell-Meiklejohn
Daniel
D
Interacting Minds, Centre for Functionally Integrative Neuroscience, University of Aarhus, Aarhus, Denmark.
Wakeley
Judi
J
Herbert
Vanessa
V
Cook
Jennifer
J
Scollo
Paolo
P
Ray
Manaan Kar
MK
Selvaraj
Sudhakar
S
Passingham
Richard E
RE
Cowen
Phillip
P
Rogers
Robert D
RD
D004298:Dopamine / Q000502:physiology*; D005260:Female; D005715:Gambling / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D007175:Impulsive Behavior / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology*; D008297:Male; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology; D050637:Receptors, Dopamine D3 / Q000187:drug effects / Q000502:physiology; D012309:Risk-Taking; D012701:Serotonin / Q000502:physiology*
D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D012701:Serotonin; D004298:Dopamine